Autolus Therapeutics plc (AUTL) Revenue History
Annual and quarterly revenue from 2015 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AUTL Revenue Growth
Revenue Breakdown (FY 2024)
AUTL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
AUTL Revenue Analysis (2015–2024)
As of May 8, 2026, Autolus Therapeutics plc (AUTL) generated trailing twelve-month (TTM) revenue of $51.1 million. The most recent quarter (Q3 2025) recorded $21.2 million in revenue, up 1.3% sequentially.
Looking at the longer-term picture, AUTL's 5-year compound annual growth rate (CAGR) stands at +28.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $10.1 million in 2024, representing a new all-time high.
Revenue diversification analysis shows AUTL's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), FATE (-51.2% YoY), and CRSP (-88.9% YoY). Compare AUTL vs KYMR →
AUTL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AUTLCurrent | $51M | - | +28.3% | -2385.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
AUTL Historical Revenue Data (2015–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.1M | +496.0% | $-130,900,000 | -1293.5% | $-241,426,000 | -2385.6% |
| 2023 | $1.7M | -72.6% | $1.7M | 100.0% | $-179,701,000 | -10583.1% |
| 2022 | $6.2M | +311.0% | $6.2M | 100.0% | $-142,893,000 | -2307.0% |
| 2021 | $1.5M | -12.1% | $1.5M | 100.0% | $-140,374,000 | -9314.8% |
| 2020 | $1.7M | -41.0% | $-133,173,000 | -7765.2% | $-303,133,000 | -17675.4% |
| 2019 | $2.9M | +178.2% | $-102,510,000 | -3525.1% | $-247,580,000 | -8513.8% |
| 2018 | $1.0M | -38.3% | $-47,253,657 | -4520.4% | $-57,533,000 | -5503.7% |
| 2017 | $1.7M | +39.7% | $684K | 40.4% | $-23,418,000 | -1383.2% |
| 2016 | $1.2M | +1187.8% | $734K | 60.6% | $-14,376,000 | -1186.1% |
| 2015 | $94K | - | $94K | 100.0% | $-8,106,583 | -8613.8% |
See AUTL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUTL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AUTL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAUTL — Frequently Asked Questions
Quick answers to the most common questions about buying AUTL stock.
Is AUTL's revenue growth accelerating or slowing?
AUTL TTM revenue: $51M. YoY growth: N/A. 5-year CAGR: +28.3%.
What is AUTL's long-term revenue growth rate?
Autolus Therapeutics plc's 5-year revenue CAGR of +28.3% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is AUTL's revenue distributed by segment?
AUTL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2024 are available for download. Segment mix reveals concentration and diversification trends.